AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
2don MSN
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback